TRVI — Trevi Therapeutics Share Price
0.000.00%
Last trade - 00:00- $244.63m
- $175.23m
- 44
- 17
- 68
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.7 | ||
| Price to Tang. Book | 3.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.38% | ||
| Return on Equity | -48.09% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Directors
- David Meeker CHM (65)
- Jennifer Good PRE (56)
- Thomas Sciascia CFD (66)
- Lisa Delfini CFO
- Danine Summers VPR
- James Cassella IND (66)
- Dominick Colangelo IND (57)
- Michael Heffernan IND (56)
- Edward Mathers IND (61)
- Anne Vanlent IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 17th, 2011
- Public Since
- May 7th, 2019
- No. of Shareholders
- 20
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 72,591,917
- Address
- 195 Church St Fl 14, NEW HAVEN, 06510-2009
- Web
- https://www.trevitherapeutics.com/
- Phone
- +1 2033042499
- Contact
- Katie Mcmanus
- Auditors
- Ernst & Young LLP
Upcoming Events for TRVI
Q3 2024 Trevi Therapeutics Inc Earnings Release
Similar to TRVI
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
What is the Trevi Therapeutics share price?
As of Today at 24:15 UTC, shares in Trevi Therapeutics are trading at $3.37. This share price information is delayed by 15 minutes.
How has the Trevi Therapeutics share price performed this year?
Shares in Trevi Therapeutics last closed at $3.37 and the price had moved by +58.96% over the past 365 days. In terms of relative price strength the Trevi Therapeutics share price has outperformed the S&P500 Index by +25.74% over the past year.
What are the analyst and broker recommendations for Trevi Therapeutics?
The overall consensus recommendation for Trevi Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Trevi Therapeutics dividend yield?
Trevi Therapeutics does not currently pay a dividend.
Does Trevi Therapeutics pay a dividend?
Trevi Therapeutics does not currently pay a dividend.
When does Trevi Therapeutics next pay dividends?
Trevi Therapeutics does not currently pay a dividend.
How do I buy Trevi Therapeutics shares?
To buy shares in Trevi Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Trevi Therapeutics?
As of the previous close price of $3.37, shares in Trevi Therapeutics had a market capitalisation of $244.63m.
Where are Trevi Therapeutics shares listed?
Here are the trading details for Trevi Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TRVI
What kind of share is Trevi Therapeutics?
Based on an overall assessment of its quality, value and momentum Trevi Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Trevi Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Trevi Therapeutics is $9.11. That is 170.33% above the last closing price of $3.37.
Analysts covering Trevi Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.46 for the next financial year.
Find out moreWhat is the trend in the Trevi Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Trevi Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -7.92%.
As of the last closing price of $3.37, shares in Trevi Therapeutics were trading +36.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Trevi Therapeutics PE Ratio?
The Trevi Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Trevi Therapeutics?
Trevi Therapeutics' management team is headed by:
- David Meeker - CHM
- Jennifer Good - PRE
- Thomas Sciascia - CFD
- Lisa Delfini - CFO
- Danine Summers - VPR
- James Cassella - IND
- Dominick Colangelo - IND
- Michael Heffernan - IND
- Edward Mathers - IND
- Anne Vanlent - IND